Blog
RSS FeedPosted by Michael Wonder on 19 Oct 2023
Tabelecleucel for the treatment of patients with a post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus
19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of ...
Posted by Michael Wonder on 19 Oct 2023
Daridorexant hydrochloride for the treatment of patients with long-term insomnia
18 October 2023 - NICE has published final evidence based recommendations on the use of daridorexant hydrochloride (Quviviq) for the ...
Posted by Michael Wonder on 19 Oct 2023
Ruxolitinib phosphate for the treatment of patients with polycythaemia vera
18 October 2023 - NICE has published final evidence based recommendations on the use of ruxolitinib phosphate (Jakavi) for the ...
Posted by Michael Wonder on 19 Oct 2023
Tofacitinib citrate for the treatment of patients with active ankylosing spondylitis
18 October 2023 - NICE has published final evidence-based recommendations on the use of tofacitinib citrate (Xeljanz) for the treatment ...
Posted by Michael Wonder on 18 Oct 2023
Rimegepant sulphate for the treatment of patients with acute migraine
18 October 2023 - NICE has published final evidence based recommendations on the use of rimegepant sulphate (Vydura) for the ...
Posted by Michael Wonder on 17 Oct 2023
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
17 October 2023 - More than 700 people set to benefit from new treatment option for advanced lymphoma. ...
Posted by Michael Wonder on 17 Oct 2023
Glofitamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
17 October 2023 - NICE has published final evidence based recommendations on the use of glofitamab (Columvi) for the treatment ...
Posted by Michael Wonder on 11 Oct 2023
Bimekizumab for the treatment of patients with axial spondyloarthritis
11 October 2023 - NICE has published final evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment ...
Posted by Michael Wonder on 09 Oct 2023
Ravulizumab for the treatment of adults with generalised myasthenia gravis
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using ravulizumab ...
Posted by Michael Wonder on 09 Oct 2023
The evolving nature of health technology assessment: a critical appraisal of NICE’s new methods manual
6 October 2023 - NICE recently completed a review of its methods for health technology assessment, involving a 2 stage ...
Posted by Michael Wonder on 08 Oct 2023
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease after two or more lines of systemic therapy
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...
Posted by Michael Wonder on 04 Oct 2023
Bimekizumab for the treatment of patients with active psoriatic arthritis
4 October 2023 - NICE has recommended evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment of ...
Posted by Michael Wonder on 04 Oct 2023
Pegunigalsidase alfa for the treatment of patients with Fabry disease
4 October 2023 - NICE has published evidence-based recommendations on the use of pegunigalsidase alfa (Elfabrio) for the treatment of ...
Posted by Michael Wonder on 03 Oct 2023
Loncastuximab tesirine for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
3 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...